Subscribe To
Zymeworks shares gain on promising data for cancer drug in development with jazz pharmaceuticals
Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their ex...
January 19, 2023, 8:07 am
Miller mendel welcomes seattle police department to the esoph background investigation network
SEATTLE, Jan. 16, 2023 (GLOBE NEWSWIRE) — Miller Mendel, Inc. welcomes the Seattle Police Department to its ...
January 16, 2023, 6:27 pm
Tulsa county sheriff’s office becomes first public safety agency in oklahoma to implement esoph background software
TULSA, Okla., Jan. 10, 2023 (GLOBE NEWSWIRE) — The Tulsa County Sheriff’s Office recently made the decision to transition to the innovative ...
January 10, 2023, 6:39 pm
Phathom pharmaceuticals announces positive topline results from phase 3 phalcon-nerd-301 trial evaluating daily dosing of vonoprazan for symptomatic non-erosive gastroesophageal reflux disease (nerd)
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn fre...
January 8, 2023, 11:00 pm
Phathom (phat) down on regulatory update on vonoprazan nda
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for tre...
January 5, 2023, 12:02 pm
Sanofi (sny) dupixent gets chmp nod to eosinophilic esophagitis
The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic ...
December 19, 2022, 3:02 pm
Phathom pharmaceuticals reports third quarter 2022 financial results and provides business updates
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosin...
November 8, 2022, 10:00 pm
Leap therapeutics to present new data from distinguish study of dkn-01 plus tislelizumab and waking study of dkn-01 plus tecentriq® at the esmo congress
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding bench...
September 4, 2022, 6:05 pm
Sanofi (sny) dupixent esophagitis kids study meets goal
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III...
July 14, 2022, 12:24 pm
Galectin: ability to potentially target unmet medical need
Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without ...
July 11, 2022, 4:16 pm
Bristol myers' (bmy) opdivo combos get fda nod for escc
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic ...
May 30, 2022, 4:33 pm
Sanofi, regeneron's dupixent gets fda nod for 4th indication (revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic ...
May 25, 2022, 3:16 am
Bristol-myers squibb snags another approval for this mega-blockbuster drug
The EC has approved its cancer drug Opdivo, together with chemotherapy, to treat esophageal cancer....
May 7, 2022, 11:07 am
Agilent (a) boosts pd-l1 ihc 28-8 pharmdx use in european union
Agilent Technologies (A) boosts its presence in the companion diagnostics market by expanding the use of PD-L1 IHC 28-8 pharmDx assay for ...
April 7, 2022, 12:48 pm
Regeneron (regn), sanofi get priority review for dupixent sbla
The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic ...
April 4, 2022, 12:03 pm
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am
Phathom pharma's digestive disease candidate meets primary goal in mid-stage study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...
February 10, 2022, 10:02 am
Pharmadrug initiates manufacturing of pd-001 for clinical programs in rare cancers and covid-19
PharmaDrug Inc announced that it has initiated the manufacturing of PD-001, a patented enteric-coated oral formulation of cepharanthine, for non-clini...
January 26, 2022, 9:34 am
Pharmadrug initiates manufacturing of pd-001 for clinical programs in rare cancers and covid-19
PharmaDrug Inc announced that it has initiated the manufacturing of PD-001, a patented enteric-coated oral formulation of cepharanthine, for non-clini...
January 26, 2022, 9:34 am